Icono twitter
Linkedin
Articles

Cost-effectiveness of ruxolitinib vs. Best Available Therapy in the treatment of myelofibrosis in Spain

Authors: Gómez-Casares MT, Hernández-Boluda JC, Jiménez-Velasco A, Martínez-López J, Ferrario MG, Gozalbo Irmina, Gostkorzewicz J, Subirá R

Journal: Journal of Health Economics & Outcomes Research (JHEOR)

Year: 2017

Reference: JHEOR 2017;5(2):162-74


Outside URL
Skip to content
Powered by  GDPR Cookie Compliance
Privacy Summary

This website uses cookies so that we can offer you the best possible user experience. Cookie information is stored in your browser and performs functions such as recognizing you when you return to our website or helping our team understand which sections of the website you find most interesting and useful.